HomeProductsBioactive CompoundsApoptosisc-RETErdafitinib
Chemical structure of CAS 1346242-81-6

Erdafitinib

CAS No.1346242-81-6
MDL No.MFCD28502040
MFC25H30N6O2
MW446.50
InChI KeyOLAHOMJCDNXHFI-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Erdafitinib is a kinase inhibitor that acts as a fibroblast growth factor receptor inhibitor, cytochrome P450 3A4 inhibitor and inducer, P-glycoprotein inhibitor, and organic cation transporter 2 inhibitor.

CAS No.1346242-81-6
Product NameErdafitinib

Biological Targets

FGFR3·FGFR1·FGFR4·FGFR2

Associated Conditions

prostate adenocarcinoma·urothelial carcinoma·cancer·non-small cell lung carcinoma·prostate carcinoma·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib.

Chemical research in toxicology • Vol. 34, Issue 7 • 2021
PMID: 34189909DOI: 10.1021/acs.chemrestox.1c00178

Erdafitinib Efficacious in Bladder Cancer.

Cancer discovery • Vol. 8, Issue 8 • 2018
PMID: 29950346DOI: 10.1158/2159-8290.CD-NB2018-085

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.

Investigational new drugs • Vol. 36, Issue 3 • 2018
PMID: 28965185DOI: 10.1007/s10637-017-0514-4

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.

Molecular cancer therapeutics • Vol. 16, Issue 6 • 2017
PMID: 28341788DOI: 10.1158/1535-7163.MCT-16-0589

Documentation